ODTX logo

Odyssey Therapeutics, Inc.

ODTX
Healthcare|Biotechnology|US
$19.23
+0.35 (+1.85%)
Tangible Book / Share
$7.53
Cash / Share
$6.79

Financials

Financial Snapshot

Market Cap
$924.2M
Enterprise Value
$867.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$177.6M
Cash & Investments
$326.0M
Net Cash
$302.5M
Free Cash Flow (TTM)
-$143.5M
Operating CF (TTM)
-$142.4M
Debt/Equity
0.06

Cash Runway & Burn Rate

Cash on Hand
$326.0M
Quarterly Burn
$35.6M
Monthly Burn
$11.9M
Est. Runway
~9.2 quarters
MetricTrend2025TTM
Cash & Investments
$181.4M$326.0M
Operating Cash Flow
-$129.5M-$142.4M
Free Cash Flow
-$130.7M-$143.5M
Capital Expenditure
-$1.2M-$1.1M
Financing Cash Flow
$215.6M$295.4M

R&D Spending

R&D (TTM)
$142.0M
R&D Intensity
—
R&D Growth vs Prior
+12.1%
MetricTrend2025TTM
Revenue
$3.0M$0.00
R&D Expense
$126.6M$142.0M
R&D % of Revenue4254.6%—
SG&A
$37.5M$35.3M

Income Statement

MetricTrend2025TTM
Revenue
$3.0M$0.00
Cost of Revenue
$0.00$1.0M
Gross Profit
$3.0M-$1.0M
R&D
$126.6M$142.0M
SG&A
$37.5M$35.3M
Operating Income
-$161.2M-$186.4M
Interest Expense
$17.0K$54.0K
Pretax Income
-$149.6M-$178.6M
Net Income
-$148.6M-$177.6M
EPS (Diluted)
-5.39-3.65
EBITDA
-$144.6M-$174.5M
Shares Out. (M)
27.5648.02

Balance Sheet

MetricTrend2025TTM
Cash & Equivalents
$41.7M$80.6M
Short-Term Investments
$139.7M$245.4M
Total Current Assets
$190.7M$337.8M
Total Assets
$269.8M$438.1M
Total Current Liabilities
$26.5M$26.1M
Long-Term Debt
$0.00$0.00
Total Liabilities
$758.1M$62.3M
Stockholders' Equity
-$488.3M$375.8M
Retained Earnings
-$568.1M-$712.2M

Cash Flow Statement

MetricTrend2025TTM
Operating Cash Flow
-$129.5M-$142.4M
Capital Expenditure
-$1.2M-$1.1M
Free Cash Flow
-$130.7M-$143.5M
Investing Cash Flow
-$103.9M-$121.8M
Financing Cash Flow
$215.6M$295.4M
Issuance of Stock
$3.2M$961.0K
Repurchase of Stock
$0.00$0.00
Net Debt Issuance
$0.00-$117.0K
Stock Based Comp.
$14.3M$18.9M
Net Change in Cash
-$17.4M$31.4M

Dilution Tracker

Shares Outstanding
48M
5-Year Share Growth
+0.0%
Stock Issuance (TTM)
$961.0K
MetricTrend2025TTM
Shares Out. (M)
27.5648.02
Change vs Prior %—74.2%
Stock Issuance
$3.2M$961.0K
Stock Repurchase
$0.00$0.00
Stock Based Comp.
$14.3M$18.9M

Margins & Profitability

MetricTrend2025TTM
Gross Margin %100.0%—
Operating Margin %-5415.2%—
Net Margin %-4994.9%—
EBITDA Margin %-4860.4%—
FCF Margin %-4391.8%—
ROE %
30.4%330.5%
ROA %
-55.1%-40.5%
ROIC %
-64.4%-44.4%
R&D / Revenue %4254.6%—

Valuation

P/E (TTM)At Loss
P/S0.00
P/B2.46
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss

Intrinsic Value Models (per share)

Tangible Book / Share
$7.53
Net Current Assets / Share
$5.73
Graham Net-Net
$5.49
Cash / Share
$6.79
MetricTrend2025TTM
P/E Ratio
-3.05-5.27
P/S Ratio
152.070.00
P/B Ratio
-0.932.46
EV/EBITDA
-3.03-4.97
EV/Revenue
147.170.00

Analyst Estimates & Quality

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$3.0M$3.0M$3.0M
Net Income-$168.4M-$133.9M-$115.5M
EPS$-5.87$-4.45$-4.27
# Analysts (EPS)557